Abbott gets FDA approval for automated blood-screening tests for hepatitis B

By Elaine Rigoli

Tampa, Fla., July 18 - Abbott has received approval from the Food and Drug Administration for its Abbott Prism hepatitis B surface antigen (HBsAg) and its Prism HBsAg confirmatory test.

These tests can be used by laboratory technicians to screen donated blood for HBsAg.

Used in more than 30 countries, the Prism system was recently approved for use in the United States with its first hepatitis B test, Prism HBcore, introduced in October. Additional hepatitis and retrovirus screening tests are under FDA review.

"We continue to focus on expanding our automated hepatitis testing menus across all of our diagnostic platforms," said Don Patton, vice president of global diagnostic commercial operations, in a news release.

"We also will continue to leverage our scientific expertise and understanding of viral hepatitis in introducing new diagnostic tests to support laboratory needs in infectious disease testing," he added.

Abbott develops in-vitro diagnostics and instrument systems and is based in Abbott Park, Ill.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.